Point72 Hong Kong LTD Immuno Gen, Inc. Transaction History

Point72 Hong Kong LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $325,292 - $469,786	72,610 New	72,610 $347,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $103,313 - $188,916	-32,798 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $136,277 - $239,285	31,990 Added 3959.16%	32,798 $156,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $3,838 - $6,060	808 New	808 $6,000
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $16,048 - $25,998	-2,469 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $9,135 - $18,912	2,469 New	2,469 $16,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $229 - $591	-102 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $17,704 - $27,035	-7,975 Reduced 98.74%	102 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $14,070 - $25,796	7,817 Added 3006.54%	8,077 $18,000
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $3,880 - $9,515	-1,610 Reduced 86.1%	260 $1,000
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $7,367 - $18,139	1,870 New	1,870 $9,000
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $8,158 - $10,412	-857 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $1,956 - $3,781	292 Added 51.68%	857 $9,000
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $2,864 - $4,474	565	565 $4,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.